Betton G R, Salmon G K
Scand J Gastroenterol Suppl. 1984;101:103-8.
The new long acting histamine H2-receptor antagonist was administered to rats at doses of 1000, 200 and 40 mg/kg body weight. Forestomach lesions of marked focal hyperplasia and hyperkeratosis were observed at a 48% incidence after 1 year daily gavage dosing with 1000 mg/kg. Lesions of this type were not seen in mid- and low-dose groups. The basal epithelium was convoluted and showed frequent mitotic figures. Two cases (4%) showed hyperplastic epithelium penetrating the muscularis mucosae. Recovery high-dose animals left untreated for a further 20-22 weeks were examined by endoscopy and necropsy and showed the hyperplasia and associated hyperkeratosis to be reversible. As penetration of the muscularis mucosae was only present in two cases at 1 year, the reversibility of this stage could not be assessed and the significance of the lesion will be determined by the results of a 2 year carcinogenicity study.
将新型长效组胺H2受体拮抗剂以1000、200和40mg/kg体重的剂量给予大鼠。在以1000mg/kg每日灌胃给药1年后,观察到前胃出现明显的局灶性增生和角化过度病变,发生率为48%。中剂量和低剂量组未出现此类病变。基底上皮呈卷曲状,可见频繁的有丝分裂象。两例(4%)显示增生的上皮穿透黏膜肌层。对高剂量组未再治疗20 - 22周的恢复动物进行内镜检查和尸检,结果显示增生及相关的角化过度是可逆的。由于1年后仅有两例出现黏膜肌层穿透,因此无法评估该阶段的可逆性,病变的意义将通过两年致癌性研究的结果来确定。